Materials and Methods Related to Sodium/Potassium Adenosine Triphosphatase and SRC
AssigneeThe University of Toledo
InventorsZi-Jian Xie, Qiqi Ye, Zhichuan Li
Life of this patent
Estimating the term…
Abstract
Described herein are methods to bind a compound to the SH2 domain of Src in a Src-expressing cell which includes contacting a compound comprising an amino acid compound to a Src-expressing cell; and binding a compound to the SH2 domain of Src.
Claims26
A method to bind a compound to the SH2 domain of Src in a Src-expressing cell comprising:
- a) contacting a compound comprising an amino acid compound consisting of the sequence STNCV EGTAR GIVVY TGD [SEQ ID NO:
- 1] to a Src-expressing cell;
- and
- b) binding a compound to the SH2 domain of Src.
A method of treating a Src-associated disease in a mammal in need of such treatment comprising:
- a) administering to a mammal a therapeutic composition comprising an amino acid compound consisting of the sequence STNCV EGTAR GIVVY TGD [SEQ ID NO:
- 1];
- and
- b) treating a Src-associated disease in the mammal.
A method of treating cancer in a mammal in need of such treatment comprising:
- a) administering to a mammal a composition comprising an amino acid compound consisting of the sequence STNCV EGTAR GIVVY TGD [SEQ ID NO:
- 1];
- and
- b) treating cancer in the mammal.
A method of treating a cardiovascular disease in a mammal in need of such treatment comprising:
- a) administering to a mammal a composition comprising an amino acid compound consisting of the sequence STNCV EGTAR GIVVY TGD [SEQ ID NO:
- 1];
- and
- b) treating a cardiovascular disease in the mammal.
A method of treating tissue fibrosis in a mammal in need of such treatment comprising:
- a) administering to a mammal a composition comprising an amino acid compound consisting of the sequence STNCV EGTAR GIVVY TGD [SEQ ID NO:
- 1];
- and
- b) treating a cardiovascular disease in the mammal.
A method to screen for test compositions capable of inhibiting binding between CD2 domain of Na/K ATPase and SH2 domain of Src, comprising the steps of:
- a) incubating test compositions with purified Src for at least 5 and up to 45 minutes in a vessel;
- b) introducing Na/KATPase to the vessel for at least 5 minutes and up to 45 minutes;
- c) introducing ouabain to the vessel for at least 1 minute and up to 45 minutes;
- d) introducing Mg2+/ATP to the vessel for at least 0.5 minute and up to 45 minutes;
- e) conducting western blot analysis to determine if Src activation was induced by ouabain.
A method to screen for test compositions capable of inhibiting binding between CD2 domain of Na/K ATPase and SH2 domain of Src, comprising the steps of:
- a) contacting a test composition with a FRET pair of CD2 domain and SH2 domain;
- and
- b) identifying those compositions which abolish the FRET energy as capable of inhibiting the CD2/SH2 interaction.
Dependencies are inferred from the claim text.